Post-Treatment Surveillance After Conisation for CIN2/3 in Norway: Long-Term CIN3+ Risk Stratification Comparing HPV DNA Testing with Cytology/HPV16/18/45 mRNA Co-Testing

We compared surveillance strategies in a retrospective regional cohort of 2136 women who underwent conisation for cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) in 2016–2020. Using results from the first eligible visit 90–548 days after treatment, we evaluated cytology, human papillomavirus (HPV) DNA testing and HPV16/18/45 E6/E7 messenger RNA (mRNA) testing, individually and in combination. We also evaluated an exploratory referral strategy adapted from the Addressing the Need for Advanced HPV Diagnostics (ATHENA) study. Histological outcomes were ascertained through 2025. Median available administrative follow-up was 7.24 years. CIN3+ (CIN3, adenocarcinoma in situ or invasive cervical cancer) was recorded in 74 women (3.5%). For CIN3+, HPV DNA testing had 93.2% sensitivity, 78.0% specificity and 24.4% positivity. Adding mRNA positivity to high-grade+ cytology increased CIN3+ sensitivity from 60.8% to 82.4%, with 92.1% specificity and 10.4% test positivity. Combining ASC-US+ cytology with mRNA positivity achieved the highest observed CIN3+ sensitivity (95.9%), with 73.5% specificity. The ATHENA-derived strategy achieved 90.5% sensitivity and 83.1% specificity, with 19.4% classified as referral-positive. Among women with equivocal or low-grade cytology, CIN3+ was recorded in 18.6% with positive mRNA and 2.5% with negative mRNA. Cytology and genotype-specific mRNA co-testing may support risk stratification after conisation. Prospective evaluation is needed to establish safe surveillance intervals.

Authors

Institutions

Publication Details

Journal
Pathogens
Published
2026-11-20
DOI
https://doi.org/10.3390/pathogens15111221
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Post-Treatment Surveillance After Conisation for CIN2/3 in Norway: Long-Term CIN3+ Risk Stratification Comparing HPV DNA Testing with Cytology/HPV16/18/45 mRNA Co-Testing

Elin H. Richardsen, Mona Antonsen, Bente Marie Falang, Sveinung Wergeland Sørbye
1 links
Pathogens
Cervical Cancer and HPV Research
article

Post-Treatment Surveillance After Conisation for CIN2/3 in Norway: Long-Term CIN3+ Risk Stratification Comparing HPV DNA Testing with Cytology/HPV16/18/45 mRNA Co-Testing

Elin H. Richardsen, Mona Antonsen, Bente Marie Falang, Sveinung Wergeland Sørbye
article en

Abstract

We compared surveillance strategies in a retrospective regional cohort of 2136 women who underwent conisation for cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) in 2016–2020. Using results from the first eligible visit 90–548 days after treatment, we evaluated cytology, human papillomavirus (HPV) DNA testing and HPV16/18/45 E6/E7 messenger RNA (mRNA) testing, individually and in combination. We also evaluated an exploratory referral strategy adapted from the Addressing the Need for Advanced HPV Diagnostics (ATHENA) study. Histological outcomes were ascertained through 2025. Median available administrative follow-up was 7.24 years. CIN3+ (CIN3, adenocarcinoma in situ or invasive cervical cancer) was recorded in 74 women (3.5%). For CIN3+, HPV DNA testing had 93.2% sensitivity, 78.0% specificity and 24.4% positivity. Adding mRNA positivity to high-grade+ cytology increased CIN3+ sensitivity from 60.8% to 82.4%, with 92.1% specificity and 10.4% test positivity. Combining ASC-US+ cytology with mRNA positivity achieved the highest observed CIN3+ sensitivity (95.9%), with 73.5% specificity. The ATHENA-derived strategy achieved 90.5% sensitivity and 83.1% specificity, with 19.4% classified as referral-positive. Among women with equivocal or low-grade cytology, CIN3+ was recorded in 18.6% with positive mRNA and 2.5% with negative mRNA. Cytology and genotype-specific mRNA co-testing may support risk stratification after conisation. Prospective evaluation is needed to establish safe surveillance intervals.

PathogensVol. 15(11)
University Hospital of North Norway (NO), UiT The Arctic University of Norway (NO)
Good health and well-being
Cervical Cancer and HPV Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Post-Treatment Surveillance After Conisation for CIN2/3 in Norway: Long-Term CIN3+ Risk Stratification Comparing HPV DNA Testing with Cytology/HPV16/18/45 mRNA Co-Testing — Elin H. Richardsen, Mona Antonsen, et al. · Pathogens (2026) | TGRS Research Map | TGRS